Nuveen LLC Invests $1.15 Million in Simulations Plus, Inc. $SLP

Nuveen LLC bought a new position in Simulations Plus, Inc. (NASDAQ:SLP) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 47,067 shares of the technology company’s stock, valued at approximately $1,154,000. Nuveen LLC owned about 0.23% of Simulations Plus as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Fifth Third Bancorp lifted its holdings in Simulations Plus by 33.8% in the first quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company’s stock worth $36,000 after acquiring an additional 375 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Simulations Plus by 42.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company’s stock valued at $72,000 after buying an additional 764 shares during the last quarter. US Bancorp DE raised its holdings in shares of Simulations Plus by 15.6% during the first quarter. US Bancorp DE now owns 6,576 shares of the technology company’s stock valued at $161,000 after buying an additional 889 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Simulations Plus during the first quarter valued at approximately $210,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Simulations Plus by 4.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,103 shares of the technology company’s stock valued at $254,000 after buying an additional 380 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Price Performance

Shares of NASDAQ:SLP opened at $14.17 on Tuesday. Simulations Plus, Inc. has a 12 month low of $12.39 and a 12 month high of $37.67. The stock has a market cap of $285.24 million, a price-to-earnings ratio of -4.50 and a beta of 0.85. The stock’s 50 day moving average price is $14.78 and its 200 day moving average price is $23.76.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Monday, July 14th. The technology company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.19. The firm had revenue of $20.36 million for the quarter, compared to analyst estimates of $22.83 million. Simulations Plus had a negative net margin of 78.63% and a positive return on equity of 11.62%. The firm’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.27 earnings per share. On average, sell-side analysts expect that Simulations Plus, Inc. will post 1.09 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SLP shares. JMP Securities reaffirmed a “market perform” rating on shares of Simulations Plus in a report on Wednesday, June 18th. KeyCorp cut Simulations Plus from an “overweight” rating to a “sector weight” rating in a report on Tuesday, July 15th. Zacks Research raised Simulations Plus to a “hold” rating in a report on Tuesday, August 12th. BTIG Research dropped their target price on Simulations Plus from $41.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, July 7th. Finally, William Blair reissued an “outperform” rating on shares of Simulations Plus in a report on Tuesday, July 15th. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Simulations Plus has an average rating of “Moderate Buy” and a consensus price target of $26.50.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.